Overview

Safety Study in Subjects With Crohn's Disease

Status:
Terminated

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This study is an open label extension of study 20090072 with subjects with Crohn's disease. Subjects will receive 350 mg AMG 827 intraveneously every 4 weeks for approximately 2 and a half years. The study will be evaluated for safety and efficacy of AMG 827.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Brodalumab